Evidence map›Paper›PMID 37046547›Full record

ReviewDiagnostics (Basel, Switzerland)2023

Applications of Machine Learning in Chronic Myeloid Leukemia.

Mohamed Elhadary, Ahmed Adel Elsabagh, Khaled Ferih, Basel Elsayed, Amgad M Elshoeibi, Rasha Kaddoura, Susanna Akiki, Khalid Ahmed, Mohamed Yassin

Open access · goldAbstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Mohamed ElhadaryCollege of Medicine, QU Health, Qatar University, Doha 2713, Qatar.ORCID 0000-0003-3075-9600
Ahmed Adel ElsabaghCollege of Medicine, QU Health, Qatar University, Doha 2713, Qatar.ORCID 0000-0002-4927-9888
Khaled FerihCollege of Medicine, QU Health, Qatar University, Doha 2713, Qatar.ORCID 0000-0003-0562-8123
Basel ElsayedCollege of Medicine, QU Health, Qatar University, Doha 2713, Qatar.ORCID 0000-0002-5983-0135
Amgad M ElshoeibiCollege of Medicine, QU Health, Qatar University, Doha 2713, Qatar.ORCID 0000-0002-2266-7784
Rasha KaddouraPharmacy Department, Heart Hospital, Hamad Medical Corporation (HMC), Doha 3050, Qatar.ORCID 0000-0003-2613-9759
Susanna AkikiDiagnostic Genomic Division, Hamad Medical Corporation (HMC), Doha 3050, Qatar.
Khalid AhmedDepartment of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha 3050, Qatar.
Mohamed YassinHematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha 3050, Qatar.ORCID 0000-0002-1144-8076
Qatar University · QAHamad Medical Corporation · QANational Center for Cancer Care and Research · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by dysregulated growth and the proliferation of myeloid cells in the bone marrow caused by the BCR-ABL1 fusion gene. Clinically, CML demonstrates an increased production of mature and maturing granulocytes, mainly neutrophils. When a patient is suspected to have CML, peripheral blood smears and bone marrow biopsies may be manually examined by a hematologist. However, confirmatory testing for the BCR-ABL1 gene is still needed to confirm the diagnosis. Despite tyrosine kinase inhibitors (TKIs) being the mainstay of treatment for patients with CML, different agents should be used in different patients given their stage of disease and comorbidities. Moreover, some patients do not respond well to certain agents and some need more aggressive courses of therapy. Given the innovations and development that machine learning (ML) and artificial intelligence (AI) have undergone over the years, multiple models and algorithms have been put forward to help in the assessment and treatment of CML. In this review, we summarize the recent studies utilizing ML algorithms in patients with CML. The search was conducted on the PubMed/Medline and Embase databases and yielded 66 full-text articles and abstracts, out of which 11 studies were included after screening against the inclusion criteria. The studies included show potential for the clinical implementation of ML models in the diagnosis, risk assessment, and treatment processes of patients with CML.

Indexed as

artificial intelligencechronic myeloid leukemiaconvolutional neural networkshemoglobinopathiesmachine learning

Identifiers

PMID37046547
PMCPMC10093579
OpenAlexW4362559708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.